DearSir,
I
amDr.NiluferYesilirmak,fromtheDepartmentof Cornea,BascomPalmerEyeInstitute,Miami,Florida, USA.Wewrotetoreportareductionofgraftrejectionwith dexamethasoneintravitrealimplant(Ozurdex 誖 )inacase withaphakia. Ozurdex誖 (AllerganInc.,Irvine,CA,USA)isanintravitreal implantcontainingabiodegradablematerialcombinedwith theactivedrugdexamethasone.Itisasmallrod-shaped, 0.46mmindiameterand6mminlength.Insidetheeye,it providessustaineddeliveryof0.7mgofpreservative-free dexamethasonetothevitreouscavityandretinaforupto 180d [1] .Thisimplantisprovedtobeeffectiveinthetreatment ofmacularedemafollowingbranchorcentralretinalvein occlusions,posteriornon-infectiousuveitis,diabeticmacular edema,pseudophakicmacularedemaandneovascular age-relatedmaculardegeneration [2] . [3] .Guilbert [4] observedthatlensstatusinfluencedtheriskofrejectionas well.Besides,severeallograftrejectionepisodesresultsin endothelialcelldensitydecreasethatleadstoalower reversibilityrate [5] .Ourcasehadbothaphakiaandrejection episodesthatmighthaveincreasedtheendothelialfailure.
Corticosteroidsareusuallystrongesttoolstoreversegraft rejectionusually.Eventhoughourcasereceivedintensive topicaland subtenoncorticosteroidtherapy,rejection progressed.Duetothefactthatthe combinationof subconjunctivalandtopicalcorticosteroidswasreported [6] as moreeffectiveinreversingrejectionthantreatmentwitha singlepulseofmethylprednisolone(500mg)incombination withthetopicalcorticosteroids,wedecidedtouseOzurdex誖 duetoitslonglastingeffect.Besidesthepatientcouldnot tolerateimmunomodulatortherapies.Oneweekafterthe implantation,theimplantdissolvedandpassedtoanterior chambereasilyduetotheaphakicandvitrectomizedeye.At thefollowingexamination,therejectionwassignificantly regressed.Incontrastthis,accordingtoliteraturethereare somestudiesshowingtheOzurdex 誖 implantmigrationto theanteriorchamberinaphakiceyes,whichresultedwith cornealdecompensationduetothedirectcontactofthe implanttotheendothelium [7] [8] [9] .Even,Mar侏n-Lamb侏es [10] consideredthattheimplantofthesedevicesinaphakic patientsshouldbecontraindicated. Chang-Lin [11] showedtheconcentrationof dexamethasoneinthevitreousandretinaraisedtohighlevels within60dofimplantation,extendingthetherapeuticperiod to6moandMyung [12] showedthedurationofitseffect wasapproximately3-4mo.Ithasbeenmentionedthat,in vitrectomizedeyesthehalf-lifeofdrugsafterintravitreal injectionreducesandthedrugclearanceincreasesfromthe vitreous [13] .Resemblingtoaforementionedstudy,the Ozurdex ® reacheditsmaximumeffectwithin2moandinstead of6mo,itcompletelydissolvedwithin3mo,inourcase. Inlong-termusageofcorticosteroids,adverseeffectssuchas glaucomaandcataractmayappear.Itisreportedthat Ozurdex 誖 cancauselowerincidenceofIOPelevation requiringsurgeryandcataractextractionthantheother intravitrealcorticosteroids [14] . 
